COMP <GO>
RPRX vs ABBV // REVENUE GROWTH (YOY)
Royalty Pharma plc Class A Ordinary Shares (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: RPRX 8
— ABBV 7
▲ REVENUE GROWTH (YOY) LEADER: ABBV
LAST: $67.18 (+1.90%) • MKT CAP: $37.91B
revenue-growth
5.10%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RPRX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RPRX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 7.00% | 29.00% | -22.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 27.8x | 33.3x | -5.50 | RPRX | /valuation <GO> |
| Free Cash Flow Yield | 6.29% | 3.47% | +2.82 | RPRX | /fcf-yield <GO> |
| Operating Margin | 65.60% | 24.60% | +41.00 | RPRX | /operating-margins <GO> |
| Net Profit Margin | 32.40% | 6.90% | +25.50 | RPRX | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 5.10% | 8.60% | -3.50 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.90 | 5.33 | -2.43 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | RPRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.40% | -0.70 | RPRX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 76.7 | 72.8 | +3.95 | RPRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 1.15 | -0.21 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 45.8x | 113.1x | -67.30 | RPRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $37.91B | $513.86B | -$475.95B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RPRX REV | ABBV REV | RPRX GROSS % | ABBV GROSS % | RPRX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.38B | $61.16B | 44.0% | 70.2% | $2.38B | $17.82B |
| FY 2024 | $2.26B | $56.33B | 44.0% | 70.0% | $2.67B | $17.83B |
| FY 2023 | $2.35B | $54.32B | 44.0% | 44.0% | $2.88B | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RPRX // BETA 0.94
ABBV // BETA 1.15